Sunshine Biopharma Inc
NASDAQ:SBFM
Balance Sheet
Balance Sheet Decomposition
Sunshine Biopharma Inc
Sunshine Biopharma Inc
Balance Sheet
Sunshine Biopharma Inc
| Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
22
|
16
|
10
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
22
|
16
|
10
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
4
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
4
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
6
|
11
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
2
|
27
|
25
|
26
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
0
+86%
|
0
-49%
|
0
+27%
|
0
-77%
|
0
+361%
|
1
+371%
|
0
-90%
|
0
+302%
|
1
+346%
|
0
-91%
|
1
+966%
|
2
+111%
|
29
+1 227%
|
27
-6%
|
31
+12%
|
|
| Liabilities | |||||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
6
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
3
|
1
|
|
| Total Current Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
0
|
7
|
6
|
6
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Total Liabilities |
0
N/A
|
0
-21%
|
0
-73%
|
0
+2 033%
|
0
-39%
|
1
+1 262%
|
1
+139%
|
0
-78%
|
1
+203%
|
1
+45%
|
1
-31%
|
2
+140%
|
2
0%
|
8
+283%
|
6
-19%
|
7
+15%
|
|
| Equity | |||||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1
|
2
|
2
|
3
|
5
|
7
|
9
|
13
|
14
|
16
|
17
|
20
|
33
|
59
|
64
|
69
|
|
| Additional Paid In Capital |
1
|
2
|
2
|
3
|
5
|
7
|
8
|
12
|
12
|
16
|
17
|
19
|
33
|
81
|
84
|
93
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Total Equity |
0
N/A
|
0
+100%
|
0
-47%
|
0
-32%
|
0
N/A
|
0
-4 750%
|
1
-54%
|
0
+65%
|
1
-173%
|
0
+90%
|
1
-1 213%
|
1
-30%
|
0
N/A
|
22
+10 102%
|
21
-2%
|
24
+11%
|
|
| Total Liabilities & Equity |
0
N/A
|
0
+86%
|
0
-49%
|
0
+27%
|
0
-77%
|
0
+361%
|
1
+371%
|
0
-90%
|
0
+302%
|
1
+346%
|
0
-91%
|
1
+966%
|
2
+111%
|
29
+1 227%
|
27
-6%
|
31
+12%
|
|
| Shares Outstanding | |||||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|